Clinical trial

Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness: A Retrospective Multi-institutional Cohort Analysis

Name
NSCLC-TDLN-001
Description
The goal of this retrospective cohort analysis is to discover the impact of the involvement extent of tumor-draining lymph nodes (TDLNs) in patients who received neoadjuvant immunochemotherapy. The main question it aims to answer is the role of TDLN in the prediction of treatment effectiveness. Researches will compare tumor-draining lymph nodes metastasis (mTDLNs) group and non-draining lymph nodes metastasis (mNDLNs) group to see whether different metastatic patterns of mediastinal lymph nodes can indicate the treatment effectiveness.
Trial arms
Trial start
2017-01-01
Estimated PCD
2024-03-01
Trial end
2024-04-01
Status
Completed
Treatment
Immunotherapy
Received neoadjuvant chemotherapy plus immunotherapy
Arms:
Neoadjuvant immunochemotherapy NSCLC group
Other names:
Chemotherapy
Size
209
Primary endpoint
Complete pathologic response
through study completion, an average of 3 months
Eligibility criteria
Inclusion Criteria: * pathologically-confirmed diagnosis of NSCLC by pretreatment biopsy * clinically staged as T1-4N0-2M0 * having undergo neoadjuvant chemoimmunotherapy * the agents of immune checkpoint inhibitors (ICIs) belong to PD-1/L1 inhibitors * having undergo surgery with lymph nodes (LNs) dissection * having postoperative pathology reports with evaluation of primary tumor and LNs response * having accessible pretreatment and preoperative radiology examinations imaging or reports Exclusion Criteria: * using PD-1/L1 inhibitors in the phase of clinical trials * the agents of neoadjuvant therapy including angiogenesis inhibitors * having undergone radiotherapy to treat primary tumor or metastatic LNs before surgery
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 209, 'type': 'ACTUAL'}}
Updated at
2024-05-14

1 organization

1 drug

1 indication

Indication
lung cancer